Nanoparticles Containing Multiple Cleavable Prodrugs For Cancer Therapy

SUMMARY

Specially designed nanoparticles to deliver multiple cancer drugs at once, improving drug stability, targeting tumors more effectively, and reducing side effects by controlling and triggering drug release directly at the tumor site.

The Unmet Need: Strategies to overcome drug degradation, off-target metabolism, and insufficient tumor penetration with synchronized delivery of multiple chemotherapeutic agents

• Cancer chemotherapy remains a cornerstone of cancer treatment, but its effectiveness is often limited by the inability to deliver multiple drugs simultaneously at optimal concentrations to tumor sites. The field of nanomedicine has emerged to address these challenges by engineering nanoscale carriers that can encapsulate and transport chemotherapeutic agents directly to cancer cells. The rationale for this approach is to improve the therapeutic index of anticancer drugs by enhancing their accumulation in tumors while minimizing systemic toxicity. As cancer is a highly heterogeneous disease, combination therapy—using multiple drugs with different mechanisms of action—is frequently required to overcome drug resistance and achieve better clinical outcomes. However, achieving precise co-delivery and controlled release of multiple drugs remains a significant challenge, underscoring the need for advanced delivery platforms that can accommodate both hydrophilic and hydrophobic agents.
• Current approaches to combination chemotherapy typically rely on administering free drugs or simple drug mixtures, which often suffer from poor pharmacokinetic profiles, rapid clearance, and non-specific distribution throughout the body. These limitations lead to suboptimal drug concentrations at the tumor site and increased exposure of healthy tissues to toxic agents, resulting in severe side effects and reduced patient compliance. Furthermore, conventional drug carriers, such as liposomes or polymeric nanoparticles, often struggle to encapsulate multiple drugs with disparate solubility profiles and to release them in a controlled, tumor-specific manner.

The Proposed Solution: A novel nanoparticle design that integrates a nanoscale coordination polymer core with a lipid coating, enabling the simultaneous delivery of multiple chemotherapeutic agents through encapsulated prodrugs

• The faculty inventor developed a nanoparticle drug delivery system designed for cancer therapy. The nanoparticles feature a core-shell architecture, with a nanoscale coordination polymer (NCP) core that encapsulates hydrophilic chemotherapeutic agents and a lipid-based shell formed by self-assembling prodrugs. Each prodrug consists of a chemotherapeutic drug moiety linked to a lipid moiety via a cleavable carbonate linker, enabling controlled and triggered drug release. The system supports the simultaneous delivery of multiple drugs, both hydrophilic and hydrophobic, and can be further enhanced with targeting agents, immunotherapy agents, or additional coating layers such as metal oxides or polymers. The nanoparticles, typically sized between 20 and 140 nanometers, are engineered to improve pharmacokinetic profiles, increase tumor accumulation, and reduce premature drug degradation and off-target effects.
• The differentiation of this technology lies in its modular and highly adaptable design, which addresses several limitations of conventional chemotherapy. By integrating both hydrophilic and hydrophobic drugs within a single nanoparticle, the platform enables combination therapies that would otherwise be challenging due to differing solubility and stability requirements. The cleavable carbonate linker ensures that drug release is both slow and responsive to the tumor microenvironment, minimizing systemic toxicity and maximizing therapeutic efficacy. The ability to modify the nanoparticle surface with targeting or immunomodulatory agents further enhances specificity and treatment outcomes. This approach not only improves drug accumulation in tumors but also reduces exposure to healthy tissues, offering a superior safety and efficacy profile compared to traditional drug delivery systems.

ADVANTAGES

ADVANTAGES

• Simultaneous delivery of multiple chemotherapeutic agents, including both hydrophilic and hydrophobic drugs

• Improved pharmacokinetic profiles with increased tumor accumulation and sustained drug release

• Controlled and triggered release of drugs to enhance therapeutic efficacy

• Versatile nanoparticle architecture allowing modification with targeting or immunotherapy agents

• Enhanced nanoparticle stability through additional coating layers such as metal oxides, polymers, or lipid bilayers

APPLICATIONS

• Targeted multi-drug cancer therapy

• Controlled-release chemotherapy formulations

• Combination immunotherapy and chemotherapy delivery

• Personalized oncology drug regimens